Special Issue "New Concepts in Musculoskeletal Medicine"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: 20 February 2024 | Viewed by 537

Special Issue Editor

Dr. Patrick Haubruck
E-Mail Website
Guest Editor
1. Heidelberg Trauma Research Group, Centre for Orthopaedics, Trauma Surgery and Spinal Cord Injury, Trauma and Reconstructive Surgery, Heidelberg University Hospital, Heidelberg, Germany
2. Raymond Purves Bone and Joint Research Laboratory, Kolling Institute, Institute of Bone and Joint Research, University of Sydney, St. Leonards, NSW 2006, Australia
Interests: orthopedic surgery; sports medicine; fracture; biomechanics; rotator cuff; trauma surgery; knee injuries

Special Issue Information

Dear Colleagues,

Musculoskeletal injury (MSI) remains a major contributor to the global burden of disease despite the many advances in the fields of musculoskeletal biology and regeneration as well as reconstructive surgery that have been made in recent years. Patients suffer from disability, continuous pain, functional impairment and associated mental comorbidities. Building upon the lessons learned over the recent years, personalized medicine and biotechnology offer the potential for novel treatment modalities; however, challenges such as a successful translation of pre-clinical results into a clinical stage remain common.

Thus, we are pleased to announce the launch of a Special Issue entitled "New Concepts in Musculoskeletal Medicine". This Special Issue will focus on cutting-edge research related to musculoskeletal medicine, orthopedic and trauma surgery, and how novel developments in personalized medicine and biotechnology can help overcome challenges of the past. We look forward to inviting authors to submit reviews or original research appropriate to this scope.

Dr. Patrick Haubruck
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • musculoskeletal
  • musculoskeletal injury
  • reconstructive surgery
  • fracture healing
  • bone tumors
  • spinal cord injury
  • osteoarthritis
  • bone healing
  • bone regeneration
  • meniscal lesions
  • ligament injuries
  • bone reconstruction
  • osteoimmunology
  • tissue engineering

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 2551 KiB  
Use of Bioactive Glass as a Bone Substitute in the Treatment of Large-Sized Bone Defects of the Femur and Tibia
J. Pers. Med. 2023, 13(12), 1644; https://doi.org/10.3390/jpm13121644 - 24 Nov 2023
Viewed by 387
Background: Managing bone defects in non-union surgery remains challenging, especially in cases of large defects exceeding 5 cm in size. Historically, amputation and compound osteosynthesis with a remaining PMMA spacer have been viable and commonly used options. The risk of non-union after fractures [...] Read more.
Background: Managing bone defects in non-union surgery remains challenging, especially in cases of large defects exceeding 5 cm in size. Historically, amputation and compound osteosynthesis with a remaining PMMA spacer have been viable and commonly used options. The risk of non-union after fractures varies between 2% and 30% and is dependent on various factors. Autologous bone grafts from the iliac crest are still considered the gold standard but are limited in availability, prompting consideration of artificial grafts. Objectives: The aims and objectives of the study are as follows: 1. To evaluate the radiological outcome of e.g., the consolidation and thus the stability of the bone (three out of four consolidated cortices/Lane-Sandhu-score of at least 3) by using S53P4-type bioactive glass (BaG) as a substitute material for large-sized bone defects in combination with autologous bone using the RIA technique. 2. To determine noticeable data-points as a base for future studies. Methods: In our clinic, 13 patients received bioactive glass (BaG) as a substitute in non-union therapy to promote osteoconductive aspects. BaG is a synthetic material composed of sodium, silicate, calcium, and phosphate. The primary endpoint of our study was to evaluate the radiological consolidation of bone after one and two years. To assess bone stabilization, we used a modified Lane-Sandhu score, considering only radiological criteria. A bone was considered stabilized if it achieved a minimum score of 3. For full consolidation (all four cortices consolidated), a minimum score of 4 was required. Each bone defect exceeded 5 cm in length, with an average size of 6.69 ± 1.92 cm. Results: The mean follow-up period for patients without final bone consolidation was 34.25 months, with a standard deviation of 14.57 months, a median of 32.00 months and a range of 33 months. In contrast, patients with a fully consolidated non-union had an average follow-up of 20.11 ± 15.69 months and a range of 45 months. Overall, the mean time from non-union surgery to consolidation for patients who achieved final union was 14.91 ± 6.70 months. After one year, six patients (46.2%) achieved complete bone consolidation according to the Lane-Sandhu score. Three patients (23.1%) displayed evident callus formation with expected stability, while three patients (23.1%) did not develop any callus, and one patient only formed a minimal callus with no expected stability. After two years, 9 out of 13 patients (69.2%) had a score of 4. The remaining four patients (30.8%) without expected stability either did not heal within two years or required a revision during that time. Conclusions: Bioactive glass (BaG) by itself or in combination with autologous bone (RIA) appears to be a suitable filler material for treating extensive non-unions of the femur and tibia. This approach seems to show non-inferiority to treatment with Tricalcium Phosphate (TCP). To ensure the success of this treatment, it is crucial to validate the procedure through a randomized controlled trial (RCT) with a control group using TCP, which would provide higher statistical power and more reliable results. Full article
(This article belongs to the Special Issue New Concepts in Musculoskeletal Medicine)
Show Figures

Figure 1

Back to TopTop